Literature DB >> 21960245

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.

A A N Giagounidis, A Kulasekararaj, U Germing, R Radkowski, S Haase, P Petersen, G Göhring, G Büsche, C Aul, G J Mufti, U Platzbecker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21960245     DOI： 10.1038/leu.2011.268

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Development of luspatercept to treat ineffective erythropoiesis.

Authors:  Anne Sophie Kubasch; Pierre Fenaux; Uwe Platzbecker
Journal:  Blood Adv       Date:  2021-03-09

Review 2.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  Where Does Lenalidomide Fit in Non-del(5q) MDS?

Authors:  Aristoteles Giagounidis
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

4.  Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.

Authors:  Francesco Pisani; Giulia Orlandi; Roberta Merola
Journal:  Case Rep Oncol       Date:  2014-04-25

5.  Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Authors:  Christian Scharenberg; Valentina Giai; Andrea Pellagatti; Leonie Saft; Marios Dimitriou; Monika Jansson; Martin Jädersten; Alf Grandien; Iyadh Douagi; Donna S Neuberg; Katarina LeBlanc; Jacqueline Boultwood; Mohsen Karimi; Sten Eirik W Jacobsen; Petter S Woll; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

6.  Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).

Authors:  Axel Rüfer; Hubert Angermann; Rudolf Benz; Nicolas Bonadies; Antonello Calderoni; Nathan Cantoni; Anna Efthymiou; Robert Escher; Geneviève Favre; Dorothea Friess; Andreas Gschwend; Andreas Himmelmann; Andreas Holbro; Peter Keller; Eirini Kouroupi; Thomas Lehmann; Nikolaus Pedarnig; Véronique Rigamonti; Kaveh Samii; Adrian Schmidt; Hans-Peter Schäfer; Roland Sperb; Georg Stüssi; Annette Winkler; Reinhard Zenhäusern; Jeroen S Goede
Journal:  Hemasphere       Date:  2022-06-17

7.  Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Authors:  Carmelo Gurnari; Alfonso Piciocchi; Stefano Soddu; Fabrizio Bonanni; Emilia Scalzulli; Pasquale Niscola; Ambra Di Veroli; Anna Lina Piccioni; Monica Piedimonte; Gianluca Maiorana; Prassede Salutari; Laura Cicconi; Michelina Santopietro; Svitlana Gumenyuk; Chiara Sarlo; Susanna Fenu; Agostino Tafuri; Roberto Latagliata; Luana Fianchi; Marianna Criscuolo; Jaroslaw P Maciejewski; Luca Maurillo; Francesco Buccisano; Massimo Breccia; Maria Teresa Voso
Journal:  Blood Cancer J       Date:  2022-09-07       Impact factor: 9.812

Review 8.  Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview.

Authors:  Mohammad Faizan Zahid; Umair Arshad Malik; Momena Sohail; Irfan Nazir Hassan; Sara Ali; Muhammad Hamza Saad Shaukat
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.